Epicutaneous immunization with myelin basic protein protects from the experimental autoimmune encephalomyelitis

Area of Science:

• Immunology
• Neuroscience
• Autoimmune Diseases

Background:

• Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system (CNS).
• Current treatment options for MS are limited.
• Oral tolerance, an experimental method to protect against autoimmune diseases, has shown limited therapeutic efficacy in clinical trials.

Purpose of the Study:

• To investigate the therapeutic potential of epicutaneous (ec) immunization with myelin basic protein (MBP) in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (EAE).
• To evaluate the impact of ec MBP immunization on immune cell infiltration in the CNS.

Main Methods:

• Mice were epicutaneously immunized with MBP.
• Experimental autoimmune encephalomyelitis (EAE) was induced in mice.
• Mononuclear cell counts in the CNS were analyzed.
• Histological examination of spinal cords was performed.

Main Results:

• Epicutaneous immunization with MBP protected mice from relapsing and remitting EAE.
• Protection correlated with a reduced number of mononuclear cells in the CNS.
• Histological analysis revealed minimal mononuclear cell infiltration in the spinal cords of ec MBP-immunized mice compared to controls.

Conclusions:

• Epicutaneous immunization with MBP is a promising strategy for protecting against experimental autoimmune encephalomyelitis.
• This approach may offer a novel therapeutic strategy for managing autoimmune CNS diseases like MS.
• Reduced immune cell infiltration in the CNS is a key mechanism underlying the protective effect.